Portal de Periódicos da CAPES

Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study

2022; Springer Nature; Volume: 126; Issue: 12 Linguagem: Inglês

10.1038/s41416-022-01752-3

1532-1827

Citadel J. Cabasag, Melina Arnold, Mark J. Rutherford, Aude Bardot, Jacques Ferlay, Eileen Morgan, Alana Little, Prithwish De, Elijah Dixon, Ryan Woods, Nathalie Saint‐Jacques, Sue Evans, Gerda Engholm, Mark Elwood, Neil D. Merrett, David Ransom, Dianne L. O’Connell, Freddie Bray, Isabelle Soerjomataram,

Colorectal Cancer Screening and Detection

The global burden of pancreatic cancer has steadily increased, while the prognosis after pancreatic cancer diagnosis remains poor. This study aims to compare the stage- and age-specific pancreatic cancer net survival (NS) for seven high-income countries: Australia, Canada, Denmark, Ireland, New Zealand, Norway, and United Kingdom. The study included over 35,000 pancreatic cancer cases diagnosed during 2012–2014, followed through 31 December 2015. The stage- and age-specific NS were calculated using the Pohar-Perme estimator. Pancreatic cancer survival estimates were low across all 7 countries, with 1-year NS ranging from 21.1% in New Zealand to 30.9% in Australia, and 3-year NS from 6.6% in the UK to 10.9% in Australia. Most pancreatic cancers were diagnosed with distant stage, ranging from 53.9% in Ireland to 83.3% in New Zealand. While survival differences were evident between countries across all stage categories at one year after diagnosis, this survival advantage diminished, particularly in cases with distant stage. This study demonstrated the importance of stage and age at diagnosis in pancreatic cancer survival. Although progress has been made in improving pancreatic cancer prognosis, the disease is highly fatal and will remain so without major breakthroughs in the early diagnosis and management.